Circulation Journal

Papers
(The H4-Index of Circulation Journal is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease194
JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease150
JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease149
JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis97
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure80
JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias74
JCS/JACR 2021 Guideline on Rehabilitation in Patients With Cardiovascular Disease61
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　― Japanese Guideline on the Management of Asymptomatic Hyperuricemia ―57
Intravascular Lithotripsy for Vessel Preparation in Severely Calcified Coronary Arteries Prior to Stent Placement　― Primary Outcomes From the Japanese Disrupt CAD IV Study ―56
Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF)55
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases50
Cardiac Arrhythmias in Autoimmune Diseases49
Impact of the COVID-19 Pandemic on Door-to-Balloon Time for Primary Percutaneous Coronary Intervention　― Results From the Singapore Western STEMI Network ―45
JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies45
Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miRNA-29c Decreases Cardiac Ischemia/Reperfusion Injury Through Inhibition of Excessive Autophagy via the PTEN/Akt/mTOR Signaling Pathway45
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias43
Lipoprotein(a) and Cardiovascular Diseases　― Revisited ―39
JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease38
JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease38
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice36
Pathophysiology of Coronary Microvascular Dysfunction36
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　― Results From the PARALLEL-HF Study ―36
Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19)36
JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction36
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention　― From the CREDO-Kyoto Registry Cohort-3 ―36
Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial34
Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury33
Optimal Timing of Venoarterial-Extracorporeal Membrane Oxygenation in Acute Myocardial Infarction Patients Suffering From Refractory Cardiogenic Shock31
Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan30
0.032147169113159